Pulmatrix more than doubles on licensing deal with JNJ's Lung Cancer Initiative

Pulmatrix

02/01/2020 14:25

** Shares of Pulmatrix Inc  PULM.O  more than double to
$1.80 premarket on licensing agreement with Lung Cancer
Initiative at Johnson & Johnson  JNJ.N  (http://bit.ly/2FbUOnB)
    ** The agreement gives Lung Cancer Initiative an option to
access kinase inhibitors being developed by PULM to intercept
lung cancer
    ** PULM is developing inhaled therapies to address serious
pulmonary diseases, using its patented iSPERSE technology, a dry
powder delivery platform 
    ** Additionally, co expects mid-stage trial results
assessing Pulmazole to treat pulmonary disease, allergic
bronchopulmonary aspergillosis
    ** PULM shares fell 69% in 2019

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 7786;))